MTOR and primary effusion lymphoma: Importantly, the dual PI3K and mTOR inhibitor NVPBEZ235 was previously shown to counteract the glycolytic phenotype of the BCBL1 PEL cell line and to delay tumor progression in a xenograft model of PEL [10].